Antenatal glucocorticoids and growth: single versus multiple doses in animal and human studies

Abstract

In recent years, many clinicians have prescribed repeated courses of glucocorticoids to pregnant women at risk of early preterm birth. The published literature has provided reassurance from randomized controlled trials that single-course treatment improves postnatal lung function without deleterious consequences, but we do not yet have data from randomized trials designed specifically to investigate the effects of repeated courses. Data from animal studies have, for many years, provided evidence that prenatal exposure to glucocorticoids restricts fetal growth and, more recently, has suggested a role in programming the individual to adult disease. Multivariate analyses from non-randomized cohorts have also suggested associations between repeated treatments and reduced birth weight, but we await results from randomized controlled trials currently in progress to provide more definitive answers. Regardless of any effect on growth, the possibility that adult health and disease may be programmed by fetal exposure to glucocorticoids will ensure our need to balance the ability of these agents to improve newborn survival with the potential consequences in later life.